SQZ Biotechnologies (OTCPK:SQZB) - Aandelenkoers, Nieuws & Analyse

SQZB Overzicht aandelen

SQZB fundamentele analyse
Sneeuwvlok Score
Waardering	2/6
Toekomstige groei	0/6
Prestaties in het verleden	0/6
Financiële gezondheid	3/6
Dividenden	0/6

Risicoanalyse

Heeft geen betekenisvolle marktkapitalisatie ( $678K )

De laatste financiële rapporten zijn meer dan een jaar oud

De omzet is het afgelopen jaar met 44.6% gedaald

Zeer volatiele aandelenkoers in de afgelopen 3 maanden

SQZ Biotechnologies Company Concurrenten

International Stem Cell

OTCPK:ISCO

US$842.5k

Theralink Technologies

OTCPK:THER

US$615.1k

Cyclacel Pharmaceuticals

NasdaqCM:CYCC

US$733.0k

NovelStem International

OTCPK:NSTM

US$520.4k

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor SQZ Biotechnologies
Historische aandelenkoersen
Huidige aandelenkoers	US$0.026
52 Week Hoogtepunt	US$0.12
52 Week Laag	US$0.01
Bèta	1.44
11 maand verandering	15.22%
3 maanden verandering	-70.56%
1 Jaar Verandering	77.84%
33 jaar verandering	-99.80%
5 jaar verandering	n/a
Verandering sinds IPO	-99.80%

Recent nieuws en updates

Recent updates

SQZ Biotechnologies Company (NYSE:SQZ) Might Not Be As Mispriced As It Looks After Plunging 30%

Jun 26

We Think SQZ Biotechnologies (NYSE:SQZ) Needs To Drive Business Growth Carefully

Jan 05

SQZ Biotechnologies GAAP EPS of -$0.77 beats by $0.06, revenue of $3.5M misses by $0.76M

Nov 09

SQZ Biotech spikes as H.C. Wainwright initiates with Buy citing platform technology

Oct 20

Is SQZ Biotechnologies (NYSE:SQZ) In A Good Position To Deliver On Growth Plans?

Aug 20

SQZ Biotechnologies GAAP EPS of -$0.78 misses by $0.01, revenue of $3.22M misses by $0.97M

Aug 04

SQZ Biotechnologies names business chief as CFO

Jul 11

Time To Worry? Analysts Just Downgraded Their SQZ Biotechnologies Company (NYSE:SQZ) Outlook

May 17

Need To Know: Analysts Are Much More Bullish On SQZ Biotechnologies Company (NYSE:SQZ)

May 16

Newsflash: SQZ Biotechnologies Company (NYSE:SQZ) Analysts Have Been Trimming Their Revenue Forecasts

Mar 25

SQZ Biotechnologies Company (NYSE:SQZ) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Mar 20

We Think SQZ Biotechnologies (NYSE:SQZ) Can Afford To Drive Business Growth

Feb 01

Rendement voor aandeelhouders

	SQZB	US Biotechs	US Markt
7D	15.2%	-3.7%	0.3%
1Y	77.8%	15.2%	31.1%

Rendement versus industrie: SQZB overtrof de US Biotechs industrie, die het afgelopen jaar een rendement 15.2 % opleverde.

Rendement versus markt: SQZB overtrof de US markt, die het afgelopen jaar een rendement opleverde van 31.1 %.

Prijsvolatiliteit

Is SQZB's price volatile compared to industry and market?
SQZB volatility
SQZB Average Weekly Movement	52.0%
Biotechs Industry Average Movement	9.8%
Market Average Movement	6.2%
10% most volatile stocks in US Market	15.8%
10% least volatile stocks in US Market	3.1%

Stabiele aandelenkoers: De aandelenkoers van SQZB is de afgelopen 3 maanden volatiel geweest.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 52% ) van SQZB is het afgelopen jaar stabiel geweest, maar is nog steeds hoger dan 75% van de aandelen US.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
2013	53	Howard Bernstein	www.sqzbiotech.com

SQZ Biotechnologies Company, een biotechnologiebedrijf in een klinische fase, ontwikkelt celtherapieën voor patiënten met kanker, auto-immuunziekten, infectieziekten en andere ernstige aandoeningen. De belangrijkste productkandidaat is SQZ-PBMC-HPV, van het SQZ Antigen Presenting Cells platform, dat zich in een Fase I klinische studie bevindt als monotherapie en in combinatie met immuno-oncologische middelen voor de behandeling van HPV16+ gevorderde of uitgezaaide solide tumoren, waaronder baarmoederhalskanker, hoofd-halskanker, anale kanker, peniskanker, vulvarkanker en vaginale kanker. Het bedrijf ontwikkelt ook SQZ-AAC-HPV, dat zich in een Fase I klinische studie bevindt voor de behandeling van HPV16+ gevorderde of gemetastaseerde solide tumoren in monotherapie en in combinaties met immuun-oncologische middelen.

SQZ Biotechnologies Company Samenvatting

Hoe verhouden de winst en inkomsten van SQZ Biotechnologies zich tot de beurswaarde?
SQZB fundamentele statistieken
Marktkapitalisatie	US$678.30k
Inkomsten(TTM)	-US$71.64m
Inkomsten(TTM)	US$12.12m

0.1x

P/S-verhouding

0.0x

Koers/Winstverhouding

Is SQZB overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
SQZB resultatenrekening (TTM)
Inkomsten	US$12.12m
Kosten van inkomsten	US$51.79m
Brutowinst	-US$39.67m
Overige uitgaven	US$31.97m
Inkomsten	-US$71.64m

Laatst gerapporteerde inkomsten

Sep 30, 2023

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	-2.43
Brutomarge	-327.29%
Nettowinstmarge	-591.07%
Schuld/Eigen Vermogen Verhouding	0%

Hoe presteerde SQZB op de lange termijn?

Bekijk historische prestaties en vergelijking

SQZB Overzicht aandelen

Risicoanalyse

SQZ Biotechnologies Company Concurrenten

OTCPK:ISCO

US$842.5k

OTCPK:THER

US$615.1k

NasdaqCM:CYCC

US$733.0k

OTCPK:NSTM

US$520.4k

Prijsgeschiedenis en prestaties

Recent nieuws en updates

SQZ Biotechnologies Files Form 15

SQZ Biotechnologies Company Contemplates Bankruptcy.

SQZ Biotechnologies Company Contemplates Bankruptcy.

SQZ Biotechnologies Reports Data for Clinical Programs at the Society for Immunotherapy of Cancer Annual Meeting

SQZ Biotechnologies Company(OTCPK:SQZB) dropped from S&P TMI Index

New major risk - Market cap size

Recent updates

SQZ Biotechnologies Files Form 15

SQZ Biotechnologies Company Contemplates Bankruptcy.

SQZ Biotechnologies Company Contemplates Bankruptcy.

SQZ Biotechnologies Reports Data for Clinical Programs at the Society for Immunotherapy of Cancer Annual Meeting

SQZ Biotechnologies Company(OTCPK:SQZB) dropped from S&P TMI Index

New major risk - Market cap size

SQZ Biotechnologies Company (NYSE:SQZ) Might Not Be As Mispriced As It Looks After Plunging 30%

SQZ Biotechnologies Receives Written Notice from the NYSE Regarding Non-Compliance with Section 802.01B of the NYSE Listed Company Manual

First quarter 2023 earnings released: US$0.60 loss per share (vs US$0.75 loss in 1Q 2022)

Price target increased by 44% to US$19.00

Full year 2022 earnings: EPS and revenues exceed analyst expectations

SQZ Biotechnologies Receives Notice Regarding Continued Listing Standards From the New York Stock Exchange

We Think SQZ Biotechnologies (NYSE:SQZ) Needs To Drive Business Growth Carefully

SQZ Biotechnologies Receives FDA Fast Track Designation for its eAPC Therapeutic Candidate for Treatment of HPV16+ Tumors and Presents Clinical Data for Multiple Programs at the European Society for Medical Oncology Immuno-Oncology Congress

High number of new directors

Price target decreased to US$15.40

SQZ Biotechnologies Announces Resignation of Micah Zajic as Chief Financial Officer, Effective December 31, 2022

Price target decreased to US$17.67

Third quarter 2022 earnings released: US$0.77 loss per share (vs US$0.80 loss in 3Q 2021)

SQZ Biotechnologies Presents Cell Squeeze® Manufacturing Platform, Linked Antigen mRNA Preclinical Research, and COMMANDER-001 Phase 1/2 Clinical Trial in Progress Poster at Society for Immunotherapy of Cancer Annual Meeting

SQZ Biotechnologies GAAP EPS of -$0.77 beats by $0.06, revenue of $3.5M misses by $0.76M

SQZ Biotech spikes as H.C. Wainwright initiates with Buy citing platform technology

Sqz Biotechnologies Publishes Preclinical Research Demonstrating Sqz® Aac Platform’S Potential as an Effective Red Blood Cell-Derived Immunotherapy

SQZ Biotechnologies Company Presents Preclinical SQZ TIL Data Supporting Potential Ability of mRNA-Driven IL-2 and IL-12 Expression to Eliminate Need for Toxic Preconditioning and Systemic IL-2 Administration for Certain T Cell Therapies

SQZ Biotechnologies Company Announces Leadership Transition

Is SQZ Biotechnologies (NYSE:SQZ) In A Good Position To Deliver On Growth Plans?

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

SQZ Biotechnologies GAAP EPS of -$0.78 misses by $0.01, revenue of $3.22M misses by $0.97M

SQZ Biotechnologies and Collaborators Publish Technology Review on SQZ(R) APCs and Effective CD8 T Cell Activation

SQZ Biotechnologies Company Appoints Micah Zajic as Principal Financial Officer

SQZ Biotechnologies names business chief as CFO

SQZ Biotechnologies Company(NYSE:SQZ) dropped from Russell 2500 Index

Price target decreased to US$25.17

SQZ Biotechnologies Announces Generation of Dopaminergic Neurons from Human Pluripotent Stem Cells Through Single-Step Delivery of Six Cell-Fate Encoding RNAs

SQZ Biotechnologies Appoints Marshelle Smith Warren as Chief Medical Officer

Independent Director recently bought US$50k worth of stock

Price target decreased to US$27.50

SQZ Biotechnologies Announces Integrated Point-Of-Care Cell Therapy Manufacturing System Demonstrated Comparable or Better Performance Than A More Conventional Clean Room-Based Process

Consensus revenue estimates fall by 14%

Time To Worry? Analysts Just Downgraded Their SQZ Biotechnologies Company (NYSE:SQZ) Outlook

First quarter 2022 earnings: EPS and revenues miss analyst expectations

SQZ Biotechnologies Company Announces First Data Presentation on Non-Clinical Studies of Point-Of-Care Manufacturing System

Here's Why We're Watching SQZ Biotechnologies' (NYSE:SQZ) Cash Burn Situation

SQZ Biotechnologies Receives FDA Fast Track Designation for its Lead Cell Therapy Candidate for the Treatment of HPV16+ Tumors

Price target decreased to US$30.60

SQZ Biotechnologies Presents New eAPC Preclinical Data Demonstrating That Multiplexed mRNA Engineering of Immune Cells Increases Killer T Cell Activity In Vivo

SQZ Biotechnologies Publishes Comprehensive Preclinical Research on SQZ TAC Platform’s Ability to Induce Multiple Key Mechanisms of Antigen-Specific Tolerance and Protect Against Type 1 Diabetes

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target decreased to US$31.00

SQZ Biotechnologies Announces Publication of Comprehensive Preclinical Research on SQZ

SQZ Biotechnologies Company Announces FDA Clearance of Investigational New Drug (IND) Application for SQZ-eAPC-HPV

Here's Why We're Watching SQZ Biotechnologies' (NYSE:SQZ) Cash Burn Situation

SQZ Biotechnologies Company Announces Lead Cell Therapy Candidate Induced Radiographic, Symptomatic and Immune Response as Monotherapy in Post-Checkpoint Hpv+ Solid Tumor Patient

SQZ Biotechnologies Lead Cell Therapy Candidate Generated Monotherapy Clinical Response Correlated with Substantial CD8 T Cell Tumor Infiltration in HPV+ Solid Tumor at Highest Dose

SQZ Biotechnologies Company Announces Acceptance by Roche Accelerator in China

Third quarter 2021 earnings released: US$0.80 loss per share (vs US$7.03 loss in 3Q 2020)

SQZ Biotechnologies Announces First Autoimmune Disease Indication for Tolerizing Antigen Carrier (TAC) Platform

Second quarter 2021 earnings released: US$0.68 loss per share (vs US$6.05 loss in 2Q 2020)

Will SQZ Biotechnologies (NYSE:SQZ) Spend Its Cash Wisely?

SQZ Biotechnologies Company(NYSE:SQZ) dropped from Russell 2500 Growth Index